Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy-Reference-Cited by-同舟云学术

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy

Published:2006 Issue:5 Volume:43 Page:954-960
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Jensen Donald M.,Morgan Timothy R.,Marcellin Patrick,Pockros Paul J.,Reddy K. Rajender,Hadziyannis Stephanos J.,Ferenci Peter,Ackrill Andrew M.,Willems Bernard

Publisher

Wiley

Subject

Hepatology

Reference8 articles.

1. Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

2. Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C

3. Diagnosis, management, and treatment of hepatitis C

4. A 48‐Week Duration of Therapy with Pegylated Interferon α2b plus Ribavirin May Be Too Short to Maximize Long‐Term Response among Patients Infected with Genotype‐1 Hepatitis C Virus

5. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin

Cited by 432 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Silicon nanoparticles (SiNPs): Challenges and perspectives for sustainable agriculture;Physiological and Molecular Plant Pathology;2023-11

2. Impact of Silicon on Plant Nutrition and Significance of Silicon Mobilizing Bacteria in Agronomic Practices;Silicon;2023-01-26

3. ՔՐՈՆԻԿ ՎԻՐՈՒՍԱՅԻՆ C ՀԵՊԱՏԻՏ. ՀԱԿԱՎԻՐՈՒՍԱՅԻՆ ԲՈՒԺՄԱՆ ՓՈՒԼԵՐԸ (ՎԵՐԼՈՒԾՈՒԹՅՈՒՆ);MEDICINE, SCIENCE AND EDUCATION;2022-05

4. Hepatitis C Treatment by Directly Acting Antiviral Agents and Its Impact on Glycemic Control;Journal of Pharmaceutical Research International;2021-05-03

5. Hepatitis C genotype 4: A report on resistance‐associated substitutions inNS3,NS5A,andNS5Bgenes;Reviews in Medical Virology;2020-06